سعر مياكالسيك 100 وحدة 5 امبول حقن عضلي او وريدي او تحت الجلد 2025

Calcitonin (salmon) 100 IU/ml solution for injection, 5 ampoules, for intramuscular, intravenous or subcutaneous use (Miacalcic, Novartis).

• Prevention of acute bone loss due to sudden immobilisation, such as in patients with recent osteoporotic fractures.Population: Adultselectronic medicines compendium (eMC)
• Paget's disease of bone, only in patients who do not respond to or are unsuitable for alternative treatments (e.g. severe renal impairment).Population: Adultselectronic medicines compendium (eMC)
• Hypercalcaemia of malignancy.Population: Adultselectronic medicines compendium (eMC)

• Very common: nausea with or without vomiting, flushing. Common: dizziness, headache, dysgeusia, diarrhoea, abdominal pain, malignancy with long-term use. Uncommon: hypersensitivity, visual disturbance, hypertension, generalised rash, pruritus. Very rare: serious allergic reactions (bronchospasm, tongue/throat swelling, anaphylactic shock).International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to calcitonin or any excipient; hypocalcaemia.International label, same formulation · electronic medicines compendium (eMC)

• Systemic allergic reactions including anaphylactic shock can occur with this peptide; skin testing is advised in patients with suspected sensitivity. Distinguish from common non-allergic flushing.International label, same formulation · electronic medicines compendium (eMC)
• Long-term calcitonin use is associated with an increased cancer risk (absolute increase 0.7-2.4% vs placebo in trials); limit duration.International label, same formulation · electronic medicines compendium (eMC)
• EMA (July 2012): because long-term calcitonin use was associated with an increased cancer risk (0.7-2.4% higher than placebo, higher with intranasal calcitonin), calcitonin nasal spray should no longer be prescribed for osteoporosis in the EU and the intranasal formulation was recommended for withdrawal.General active-ingredient information · European Medicines Agency (EMA)

• Cardiac glycosides and calcium channel blockersTransient falls in serum calcium may modify their effects; dose adjustment may be needed.electronic medicines compendium (eMC)
• BisphosphonatesAdditive calcium-lowering effect.electronic medicines compendium (eMC)
• LithiumPlasma lithium may fall; lithium dose may need adjustment.electronic medicines compendium (eMC)

• Not studied in pregnant women; use only if considered absolutely essential by the physician.International label, same formulation · electronic medicines compendium (eMC)
• Unknown whether excreted in human milk; in animals it decreased lactation and was excreted in milk; breastfeeding not recommended.International label, same formulation · electronic medicines compendium (eMC)

• Calcitonin (salmon): Acts primarily on bone; decreases the rate of bone resorption, associated with fewer osteoclasts and reduced resorptive activity (calcitonin receptors are present on osteoclasts and osteoblasts) (US label).